Mr. Garland has served as chairman of the board of directors since November 2022. He was CEO of PACT Pharma, Inc. from March 2021 to February 2023 and remains a member of its board. He was CEO of Portola Pharmaceuticals, acquired by Alexion in 2020, and led its commercial launch of Andrexxa.
The company’s Chief Executive Officer, Mr. Lettmann, has held the role since September 2023 and has been an investor and board member since its founding in 2015. He has more than 20 years of experience as a biotechnology operator and investor.
Dr. Flaherty is a professor at Harvard Medical School and director of clinical research at the Massachusetts General Hospital Cancer Center. Dr. Flaherty co-founded Loxo Oncology, served on its board until its acquisition by Eli Lilly and Company, and has served on the boards of Clovis Oncology and Checkmate Pharmaceuticals.
ALX Oncology Inc. and its subsidiaries and affiliates describe how they collect, process, share, and safeguard personal information gathered through the company website. The privacy policy also describes users’ rights and choices.
